Sarcopenia
Welcome,         Profile    Billing    Logout  
 46 Companies   12 Products   12 Products   17 Mechanisms of Action   756 Trials   22406 News 


12345678910111213...401402»
  • ||||||||||  Journal:  Pediatric reference values for total psoas muscle area in Korean children and adolescents. (Pubmed Central) -  Feb 3, 2025   
    tPMA at L3-4 and L4-5 were positively correlated with weight (r?=?0.77; r?=?0.81, P?<?0.001, both) and height (r?=?0.61; r?=?0.67, P?<?0.001, both) in females. We provided sex-specific and age-specific growth charts and developed an online calculator for tPMA at the levels of L3-4 and L4-5, which can serve as an evaluation guide for muscle mass in Korean children.
  • ||||||||||  Review, Journal:  Vitamin D and hip protectors in osteosarcopenia: a combined hip fracture preventing approach. (Pubmed Central) -  Feb 3, 2025   
    Hip protectors may act downstream attenuating the effects of falls although their use is still not yet enough widespread due to the suboptimal compliance obtained by traditional hard devices. Concomitant use of vitamin D and hip protectors may represent an effective strategy in the prevention of hip fractures which need to be tested in ad hoc designed clinical trials.
  • ||||||||||  Review, Journal:  Sarcopenia as a Risk Factor for Mortality in NAFLD: How (Pubmed Central) -  Feb 3, 2025   
    The lack of standardization in sarcopenia diagnosis for NAFLD patients is concerning. A consistent definition is necessary to prevent this comorbidity from being overlooked, improve care, and outcomes.
  • ||||||||||  Journal:  Determinants of Trunk Muscle Size Decrease in Patients with Type B Acute Aortic Dissection. (Pubmed Central) -  Feb 2, 2025   
    The days until ambulation and the length of hospital stay were slightly longer in the LD group than in the MDI group (days until ambulation, P = 0.111; length of hospital stay, P = 0.053). Logistic regression model analysis demonstrated a higher peak CRP level (OR = 3.43; 95% CI, 1.50-7.84) and larger %FL diameter (OR = 3.88; 95% CI, 1.55-9.69) were predictive of a large PLVI decrease.Our results indicate that a larger FL and subsequent exaggerated inflammatory response may result in a trunk muscle decrease in type B AAD patients.
  • ||||||||||  Journal:  Association between sarcopenia components and depressed mood varies by sex among community-dwelling older adults from the Korean Frailty and Aging Cohort Study. (Pubmed Central) -  Feb 2, 2025   
    The co-occurrence of low muscle mass and muscle strength (OR, 2.451; 95% CI, 1.007-5.964) was associated with depressed mood in men, whereas low physical performance (OR, 2.007; 95% CI, 1.275-3.160) and the coexistence of low muscle mass and physical performance (OR, 1.804; 95% CI, 1.003-3.248) correlated with depressed mood in women. Sarcopenia and depressed mood were significantly associated among older adults, underscoring the need to account for sex-specific differences in sarcopenia components when evaluating mental health outcomes to tailor interventions targeting sarcopenia and improve the mental well-being of aging populations.
  • ||||||||||  Review, Journal:  Exploring receptors for pro-resolving and non-pro-resolving mediators as therapeutic targets for sarcopenia. (Pubmed Central) -  Feb 2, 2025   
    Recent preclinical studies indicate that both SPM GPCRs and non-SPM GPCRs can mitigate symptoms of aging-related diseases such as obesity and diabetes, which are driven by chronic inflammation and metabolic disturbances. These findings suggest that targeting these receptors could provide a novel strategy for addressing various chronic inflammatory conditions, including sarcopenia.
  • ||||||||||  Review, Journal:  Skeletal Muscle Innervation: Reactive Oxygen Species as Regulators of Neuromuscular Junction Dynamics and Motor Unit Remodeling. (Pubmed Central) -  Feb 2, 2025   
    By synthesizing findings from recent studies with seminal works, including investigations of myelin and terminal Schwann cells and neuromuscular junction (NMJ) dynamics, this review provides a comprehensive understanding of the molecular mechanisms underpinning motor unit maintenance and repair. The goal is to elucidate how oxidative stress influences these processes and to explore potential therapeutic strategies for neuromuscular disorders.
  • ||||||||||  Journal:  A study on the balance ability and plantar pressure of sarcopenia patients in different standing postures. (Pubmed Central) -  Feb 2, 2025   
    Bioelectrical impedance vector analysis may effectively screen for body composition changes and nutritional status, supporting timely, multidisciplinary interventions. The difference in balance ability between sarcopenia population and non-sarcopenia population is reflected in standing posture with a relatively narrower base of support on the plantar surface (FST), and FFT stance plantar pressure can be used as a new method for screening sarcopenia.
  • ||||||||||  Journal:  Sarcopenia is associated with survival in patients awaiting kidney transplant. (Pubmed Central) -  Feb 1, 2025   
    Sarcopenia as assessed with muscle area measurements is independently associated with kidney waitlist survival. Functional ability and muscle area may be overlapping, but noncongruent, determinants of waitlist outcomes and may need to be individually assessed to create the most predictive survival model.
  • ||||||||||  Biomarker, Clinical, Retrospective data, Review, Journal:  C-Terminal Agrin Fragment as a Biomarker for Sarcopenia: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Jan 31, 2025   
    Our meta-analysis concluded that elevated CAF levels were associated with sarcopenia and decreased HGS and SMI. CAF could serve as a valuable marker for the early detection and monitoring of sarcopenia, ultimately facilitating the management and treatment of this debilitating condition.
  • ||||||||||  Review, Journal:  Multimorbidity in liver surgery (Pubmed Central) -  Jan 31, 2025   
    No abstract available In contrast, minimally invasive resection leads to a
  • ||||||||||  Trial completion date, Trial primary completion date:  POWER: Protein Supplement and Exercise Training for the Treatment of Sarcopenia Risk in Older Adults (clinicaltrials.gov) -  Jan 30, 2025   
    P=N/A,  N=40, Recruiting, 
    Providing such lifestyle interventions on the internet could reach an increased number of older adults, providing the opportunity to contribute to the health and independence of the rapidly growing aging population. Trial completion date: Aug 2025 --> May 2025 | Trial primary completion date: Dec 2023 --> May 2025